Published in Lancet on September 11, 1999
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev (2008) 1.55
Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol (2010) 1.04
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J (2004) 0.82
Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer (2004) 0.80
Molecular imaging of oncolytic viral therapy. Mol Ther Oncolytics (2015) 0.76
Genetic enhancement of radionuclide cancer therapy. Lancet (1999) 0.75
Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study. Hippokratia (2012) 0.75
Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med (1994) 2.05
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg (2007) 1.43
Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med (2000) 1.25
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol (1996) 1.11
The hidden sentinel node in breast cancer. Eur J Nucl Med Mol Imaging (2002) 1.10
I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med (1992) 1.09
First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer (1995) 1.05
Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med (1987) 1.04
Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies. Eur J Nucl Med Mol Imaging (2009) 0.98
Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol (2000) 0.98
Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med (1994) 0.97
Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer. Br J Surg (1996) 0.97
Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer (1996) 0.97
Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients. Ann Surg Oncol (2000) 0.96
Sentinel node biopsy for melanoma in the head and neck region. Head Neck (2000) 0.96
A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data. Radiother Oncol (1993) 0.94
Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med (1997) 0.91
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res (1999) 0.90
Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer (2002) 0.89
Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours. Eur J Nucl Med (1996) 0.88
The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med (1987) 0.88
Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res (1991) 0.88
Scintigraphic assessment of salivary function and excretion response in radiation-induced injury of the major salivary glands. Cancer (1994) 0.88
Improved sentinel node visualization in breast cancer by optimizing the colloid particle concentration and tracer dosage. Nucl Med Commun (2001) 0.87
Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer (1995) 0.85
Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys (1990) 0.84
Lymphoscintigraphy in oncology: a rediscovered challenge. Eur J Nucl Med (1999) 0.83
Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc (1995) 0.83
Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer (1995) 0.82
Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun (1995) 0.82
Reproducibility of lymphoscintigraphy for lymphatic mapping in cutaneous melanoma. J Nucl Med (1996) 0.82
Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy. Int J Cancer (2000) 0.82
Validation of gamma probe detection of the sentinel node in melanoma. J Nucl Med (1997) 0.81
Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion. Nuklearmedizin (1996) 0.80
[Added value of prone position technique for PET-TAC in breast cancer patients]. Rev Esp Med Nucl (2010) 0.79
Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. Eur J Nucl Med (1997) 0.79
Hypertrophic osteoarthropathy on bone scintigraphy related to a mediastinal tumour of unknown origin imaged by FDG-PET. Eur J Nucl Med Mol Imaging (2003) 0.79
A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy. Prog Clin Biol Res (1991) 0.79
Dynamic studies of lymphocytes labelled with indium-111 during and after treatment with monoclonal anti-idiotype antibody in advanced B cell lymphoma. Br Med J (Clin Res Ed) (1984) 0.79
Radionuclide therapy of neural crest tumors. Med Pediatr Oncol (1987) 0.79
Detection of lung metastases from osteosarcoma by scintigraphy using 99mTc-methylene diphosphonate. Diagn Imaging (1981) 0.79
Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction. Ann Oncol (1994) 0.79
Preliminary experience with thallous chloride T1 201-labeled single-photon emission computed tomography scanning in head and neck cancer. Arch Otolaryngol Head Neck Surg (1996) 0.79
Thallium-201 SPECT in the diagnosis of head and neck cancer. J Nucl Med (1997) 0.79
[(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts. Int J Cancer (2000) 0.78
Radiosynoviorthesis of the knee: a doubleblind trial of 1 versus 5 mCi Gold-198. Clin Rheumatol (1988) 0.78
High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction. Nucl Med Commun (2002) 0.78
Tumor and therapy associated abnormal changes on bone scintigraphy. Old and new phenomena. Clin Nucl Med (1993) 0.78
Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer (2004) 0.77
Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med (1986) 0.77
High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients. J Pharm Biomed Anal (1994) 0.77
Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. Urol Int (2006) 0.77
Iodine-125-MIBG therapy for neuroblastoma. J Nucl Med (1991) 0.77
Interference of MIBG uptake by medication: a case report. Neth J Med (1995) 0.77
Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer. Eur J Nucl Med (1994) 0.77
131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma. Bull Cancer (1988) 0.77
Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma. Diagn Imaging Clin Med (1985) 0.77
Radioimmunoscintigraphy using iodine-131-anti-CEA monoclonal antibodies and thallium-201 scintigraphy in medullary thyroid carcinoma: a case report. J Nucl Med (1990) 0.77
The clearance of heat-damaged erythrocytes by the reticulo-endothelial system in systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int (1984) 0.76
Correlative 201Tl SPECT, MRI and ex vivo 201Tl uptake in detecting and characterizing cervical lymphadenopathy in head and neck squamous cell carcinoma. J Nucl Med (1999) 0.76
Penile lymphoscintigraphy for sentinel node identification. Eur J Nucl Med (2001) 0.76
Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy. Eur J Nucl Med (1993) 0.76
Occult primary tumors of the head and neck: accuracy of thallium 201 single-photon emission computed tomography and computed tomography and/or magnetic resonance imaging. Arch Otolaryngol Head Neck Surg (2001) 0.76
Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine. Clin Nucl Med (1986) 0.75
N-isopropyl-p[123I]iodoamphetamine, a new agent for lung imaging studies. Thorax (1986) 0.75
Sequential 75SeHCAT imaging in addition to the conventional 75SeHCAT test: a necessity. Eur J Nucl Med (1995) 0.75
An original approach in the diagnosis of early breast cancer: use of the same radiopharmaceutical for both non-palpable lesions and sentinel node localisation. Eur J Nucl Med Mol Imaging (2002) 0.75
Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of Tc-Hynic-rh-Annexin V Imaging. Clin Med Oncol (2008) 0.75
[Diagnosis and therapy of neural crest tumors using I131 iodobenzylguanidine]. Ned Tijdschr Geneeskd (1988) 0.75
Intense Tl-201 uptake in a "cold" bone lesion due to metastatic thyroid carcinoma. Clin Nucl Med (1990) 0.75
Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: a report from clinical practice. Eur J Nucl Med (1993) 0.75
Contralateral inguinal lymph node metastasis in patients with melanoma of the lower extremities. Br J Surg (1989) 0.75
Unexpected brain uptake in radioimmunoscintigraphy using F(ab)2 monoclonal antibodies. Clin Nucl Med (1993) 0.75
[Pediatric oncology. Medical aspects of I-131-MIBG]. TVZ (1989) 0.75
[The role of krypton-81m-ventilation in scintigraphic studies of the lung]. Ned Tijdschr Geneeskd (1983) 0.75
Malignant bone tumors and their metastases. Ann Radiol (Paris) (1983) 0.75
Breast carcinomas detected by thallium-201 scintigraphy. Cancer Lett (1988) 0.75
Lateral and computerized transverse 99mTc-Mdp bone scintigrams to supplement the anteroposterior bone scintigram for spinal hot spot localization. Report of a case. Spine (Phila Pa 1976) (1984) 0.75
131I-rose bengal therapy in hepatoblastoma patients. Eur J Cancer (1991) 0.75
Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy. Eur J Nucl Med (1996) 0.75
[Radiation nephropathy]. Ned Tijdschr Geneeskd (1984) 0.75
[Colchicine therapy in familial Mediterranean fever]. Ned Tijdschr Geneeskd (1978) 0.75
Side effects of treatment with I-131-meta-iodobenzylguanidine (I-131-MIBG) in neuroblastoma patients. Prog Clin Biol Res (1988) 0.75
Detection of neuroblastoma with 131I-meta-iodobenzylguanidine. Prog Clin Biol Res (1985) 0.75
Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use. Nucl Med Commun (1993) 0.75
Pulmonary tumor-embolism from intravascular osteosarcoma demonstrated by bone scintigraphy. Clin Nucl Med (1982) 0.75
Unexpected pulmonary uptake of [99mTc]MDP in a patient with bronchopneumonia. Semin Nucl Med (1994) 0.75
Diagnosis and treatment of malignant pheochromocytoma with 131I-meta-iodobenzylguanidine: a case report. Radiother Oncol (1990) 0.75
Radiation pneumonitis imaged with indium-111-pentetreotide. J Nucl Med (1996) 0.75
[Scintigraphy using I 131 iodobenzylguanidine and malignant melanomas]. Ned Tijdschr Geneeskd (1990) 0.75
Scintigraphic detection of rhabdomyosarcoma. Lancet (1987) 0.75
Radiation protection during treatment of children with 131I-meta-iodobenzylguanidine. Health Phys (1986) 0.75
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab. Hum Antibodies (2011) 0.75
Detection of lymph node invasion in prostatic carcinoma with iliopelvic lymphoscintigraphy. Br J Urol (1992) 0.75
Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review. Appl Radiat Isot (1994) 0.75
Reporting of perfusion/ventilation lung scintigraphy using an anatomical lung segment chart: a prospective study. Nucl Med Commun (1994) 0.75
Multiple-view scintigraphy for localization of osteoid osteoma. Diagn Imaging (1983) 0.75
Intracystic administration of Tc-99m colloid particles to study retention and drainage in lymphangioma of the neck. Clin Nucl Med (1994) 0.75